Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

WAYNE, N.J. and EMERYVILLE, Calif., May 16 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced more than 40 data presentations at the 2008 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the potential for Nexavar(R) (sorafenib) tablets in multiple tumor types as a single agent or in combination with other agents.

"Data at ASCO will expand upon and support the proven efficacy and tolerability of Nexavar in liver cancer and advanced kidney cancer and provide new insight into the potential of Nexavar in additional types of cancer," said Henry Fuchs, MD, executive vice president and chief medical officer of Onyx Pharmaceuticals. "Highlights include studies demonstrating that Nexavar extends life for Asian patients with liver cancer; provides an effective, well-tolerated option for elderly patients with advanced kidney cancer and may provide benefit and warrants further study in heavily pretreated patients with non-small cell lung cancer."

Nexavar data highlights include:

Hepatocellular Carcinoma

-- Randomized Phase III trial of sorafenib versus placebo in Asian

patients with advanced hepatocellular carcinoma

-- Ann Lii-Cheng, MD, PhD, department of internal medicine, National

Taiwan University Hospital, Taipei, Taiwan

-- Abstract #4509, oral presentation, Monday, June 02, 2008,

4:30 - 4:45 p.m., E-Hall D2

-- Efficacy and safety of sorafenib in patients with advanced

hepatocellular carcinoma and vascular invasion or extrahepatic spread:

a subanalysis from the SHARP trial

-- Morris Sherman, MD, PhD, associate professor of medic
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
2. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
3. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
4. Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
5. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
6. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
7. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations dedicated ... has further expanded its global reach with the affiliation ... Australia, reports Mylinda Vick, CCIM, Chairman of the ITRA ... ACORPP (Australian Corporate Property and Projects) , is a ... to a wide range of clients in the private ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 BioPlus ... specialty pharmacies, announces the promotion of Nick Maroulis, Pharm.D. ... Specialty Pharmacy Services. , In this position, Dr. ... while also managing the directors of our multi-site pharmacies ... BioPlus since 1997 and during that time he has ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... FL (May 4, 2009): Uveitis, or inflammation within ... for years of visual loss roughly comparable to ... pioneering international Phase 3 program in uveitis, the ... ability of LX211 (LUVENIQ, voclosporin oral capsule) to ...
... Changes Will Result in a 35% Sales Force Reduction ... DIEGO, May 4 Amylin Pharmaceuticals, Inc. (Nasdaq: ... sales within the diabetes market. Amylin,s existing primary care ... organization that brings a specialty approach to endocrinologists and ...
... Diagnostics, LLC. (MSD) confirmed today that its investigational influenza ... of infection with the 2009 A(H1N1) swine flu. ... being developed under a contract with the Centers for ... referred to in the CDC,s Morbidity and Mortality Weekly ...
Cached Biology Technology:First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 2First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 3First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 4Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market 2Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market 3Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market 4Meso Scale Diagnostics' Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection 2
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Texas AgriLife Research program at Vernon could become a ... Malinowski, Texas AgriLife Research plant physiologist and forage agronomist ... early start about six years ago as a hobby ... Pinchak, AgriLife Research animal nutritionist, and Steve Brown, Texas ...
... "Paper of the Week" by Wai Mun Huang and ... the University of Minnesota reveals new insights into the molecular ... the pathogen responsible for crown gall disease, a tumor-forming infection ... The bacterium is parasitic: It infects its plant ...
... at the Northeast Fisheries Science Center,s Narragansett Laboratory, ... primary productivity and dissolved oxygen would lead. Now ... heads a long-term Ship of Opportunity Program (SOOP) ... platforms during their routine operations. Using an instrument, ...
Cached Biology News:Researchers take hibiscus efforts to commercialization 2Researchers take hibiscus efforts to commercialization 3NOAA plankton surveys, second longest in the North Atlantic, add to new global effort 2NOAA plankton surveys, second longest in the North Atlantic, add to new global effort 3
... monoclonal antibody which can immunocapture up to ... mitochondria. Also included are 2 mg of ... Complex V immunocapture kit allows isolation of ... small amounts of tissue. This facilitates subsequent ...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
... Rabbit polyclonal to MKK6 (phospho S207) ... applications). Antigen: ... around the phosphorylation site of Serine ... Entrez Gene ID: 5608 ...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Biology Products: